Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iradimed (IRMD) EBIAT (2016 - 2025)

Iradimed (IRMD) has disclosed EBIAT for 13 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIAT rose 10.44% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.2 million, a 13.73% increase, with the full-year FY2024 number at $19.2 million, up 11.87% from a year prior.
  • EBIAT was $5.6 million for Q3 2025 at Iradimed, down from $5.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $5.8 million in Q2 2025 to a low of $1.4 million in Q1 2021.
  • A 5-year average of $3.9 million and a median of $4.1 million in 2024 define the central range for EBIAT.
  • Biggest YoY gain for EBIAT was 510.7% in 2021; the steepest drop was 21.61% in 2021.
  • Iradimed's EBIAT stood at $3.9 million in 2021, then fell by 5.63% to $3.7 million in 2022, then rose by 23.58% to $4.5 million in 2023, then grew by 13.37% to $5.1 million in 2024, then increased by 8.35% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EBIAT are $5.6 million (Q3 2025), $5.8 million (Q2 2025), and $4.7 million (Q1 2025).